Evaluation of HER2 immunohistochemistry expression in non-standard solid tumors from a Single-Institution Prospective Cohort [0.03%]
一项单中心前瞻性队列研究中标准染色体外非典型实体肿瘤HER2免疫组化表达的评估
Saurav Verma,Amanda Chapman,Lee-Anne Pickard et al.
Saurav Verma et al.
Aim: Human epidermal growth factor receptor-2 (HER2) is a well-established prognostic and predictive biomarker. It is an FDA-approved therapeutic target for HER2 positive breast, gastroesophageal, and more recently, lung ...
Anticancer peptides as novel immunomodulatory therapeutic candidates for cancer treatment [0.03%]
抗肿瘤肽作为癌症治疗中新型免疫调节类候选药物的研究进展
Apurva Sood,V V Jothiswaran,Amrita Singh et al.
Apurva Sood et al.
Cancer remains a concern after years of research in this field. Conventional therapies such as chemotherapy, radiation, and surgery are available for cancer treatment, but they are characterized by various side effects. There are several im...
Harnessing endoscopic ultrasound-guided radiofrequency ablation to reshape the pancreatic ductal adenocarcinoma microenvironment and elicit systemic immunomodulation [0.03%]
基于内镜超声引导的射频消融重塑胰腺导管腺癌微环境并激发全身免疫调控反应
Vishali Moond,Bhumi Maniyar,Prateek Suresh Harne et al.
Vishali Moond et al.
Pancreatic ductal adenocarcinoma (PDAC) is characterized by poor prognostics and substantial therapeutic challenges, with dismal survival rates. Tumor resistance in PDAC is primarily attributed to its fibrotic, hypoxic, and immune-suppressi...
Combination of the PARPi and ARSi in advanced castration resistant prostate cancer: a review of the recent phase III trials [0.03%]
PARP抑制剂与AR信号传导抑制剂在难治性前列腺癌中的联合应用近期III期临床试验综述
Martina Panebianco,Vittore Cereda,Mario Rosario D&#x;Andrea
Martina Panebianco
Tumors with an impaired ability to repair DNA double-strand breaks by homologous recombination, including those with alterations in breast cancer 1 and 2 (BRCA1 and BRCA2) genes, are very sensitive to blocking DNA single-strand repair by in...
Therapy resistance in prostate cancer: mechanism, signaling and reversal strategies [0.03%]
前列腺癌的治疗抵抗：机制、信号传导及逆转策略
Neha Thakur,Pallavi Singh,Aditi Bagri et al.
Neha Thakur et al.
Prostate cancer (PC) depicts a major health challenge all over the globe due to its complexities in the treatment and diverse clinical trajectories. Even in the advances in the modern treatment strategies, the spectrum of resistance to the ...
A narrative review on perioperative systemic therapy in non-small cell lung cancer [0.03%]
非小细胞肺癌围手术期系统治疗的叙事性回顾
Robert Hsu,Zhaohui Liao Arter,Darin Poei et al.
Robert Hsu et al.
Non-small cell lung cancer (NSCLC) that is operable still carries a high risk of recurrence, approaching 50% of all operable cases despite adding adjuvant chemotherapy. However, the utilization of immunotherapy and targeted therapy moving b...
It might be a dead end: immune checkpoint inhibitor therapy in EGFR-mutated NSCLC [0.03%]
或为死胡同：EGFR突变型非小细胞肺癌的免疫检查点抑制剂治疗
Ken Akao,Yuko Oya,Takaya Sato et al.
Ken Akao et al.
Despite innovative advances in molecular targeted therapy, treatment strategies using immune checkpoint inhibitors (ICIs) for epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) have not progressed significantl...
Simon Gray,Nuria Santamaria,Anna Olsson-Brown
Simon Gray
Over the last decade, immune checkpoint inhibitors (ICIs) have dramatically improved the systemic treatment of multiple solid tumour types. However, they can also induce inflammation in an extensive range of normal tissues types. The entity...
Sutatip Pongcharoen,Nongphanga Kaewsringam,Poorichaya Somaparn et al.
Sutatip Pongcharoen et al.
Cancer is the primary cause of death worldwide, and conventional treatments are painful, complicated, and have negative effects on healthy cells. However, cancer immunotherapy has emerged as a promising alternative. Principle of cancer immu...
The rapidly changing treatment landscape of first-line advanced urothelial cancer (aUC) or metastatic urothelial cancer (mUC) [0.03%]
一线晚期/转移性尿路上皮癌治疗格局的迅速演变
Minira Aslanova,Eun-Mi Yu,Jeanny B Aragon-Ching
Minira Aslanova
The landscape of treatment for first-line therapy in advanced urothelial cancer (aUC) and metastatic urothelial cancer (mUC) has rapidly changed in the last year alone. Maintenance avelumab remains a viable treatment option for many patient...